Tsuneyo Mimori Selected Research

Connective Tissue Diseases (Connective Tissue Disease)

10/2020	Long-term follow-up of patients with anti-cyclic citrullinated peptide antibody-positive connective tissue disease: a retrospective observational study including information on the HLA-DRB1 allele and citrullination dependency.
1/2019	Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders.
9/2017	Anti-carbamylated Protein Antibodies Are Detectable in Various Connective Tissue Diseases.
1/2017	Splicing factor proline/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody.
1/2017	The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
12/2016	Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
1/2016	Efficacy and Safety of Grapefruit Juice Intake Accompanying Tacrolimus Treatment in Connective Tissue Disease Patients.
7/2014	GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice.
2/2014	Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases.
3/2013	Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tsuneyo Mimori Research Topics

Disease

81	Rheumatoid Arthritis 02/2022 - 12/2002
33	Dermatomyositis (Dermatopolymyositis) 11/2022 - 09/2004
30	Interstitial Lung Diseases (Interstitial Lung Disease) 11/2020 - 05/2005
23	Myositis (Idiopathic Inflammatory Myopathies) 07/2021 - 09/2004
20	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 12/2003
18	Connective Tissue Diseases (Connective Tissue Disease) 10/2020 - 02/2002
17	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 09/2002
14	Arthritis (Polyarthritis) 01/2022 - 02/2004
13	Inflammation (Inflammations) 01/2022 - 12/2002
12	Neoplasms (Cancer) 11/2022 - 01/2002
12	Polymyositis 10/2019 - 09/2004
11	Immunoglobulin G4-Related Disease 05/2020 - 02/2012
8	Melanoma (Melanoma, Malignant) 01/2020 - 09/2010
8	Amyopathic dermatomyositis 09/2019 - 05/2005
6	Takayasu Arteritis (Arteritis, Takayasu's) 05/2021 - 08/2013
5	Disease Progression 11/2020 - 05/2006
5	Drug-Related Side Effects and Adverse Reactions 05/2020 - 01/2007
5	Systemic Scleroderma (Systemic Sclerosis) 05/2015 - 07/2011
5	Mixed Connective Tissue Disease (MCTD) 02/2015 - 11/2007
5	Fever (Fevers) 05/2013 - 01/2007
4	Necrosis 01/2020 - 05/2010
4	Infections 03/2019 - 07/2016
4	Collagen Diseases (Collagen Disease) 01/2013 - 10/2003
3	Muscular Diseases (Myopathy) 01/2022 - 05/2006
3	Idiopathic Interstitial Pneumonias 01/2017 - 01/2007
3	Vasculitis (Vasculitides) 06/2016 - 03/2011
3	Rheumatic Diseases (Rheumatism) 07/2015 - 01/2007
3	Antisynthetase syndrome 11/2014 - 03/2011
3	Experimental Arthritis 01/2011 - 10/2005
3	Vascular Diseases (Vascular Disease) 08/2010 - 09/2004
2	Body Weight (Weight, Body) 01/2022 - 01/2012
2	Proteinuria 12/2021 - 01/2016
2	Hypoxia (Hypoxemia) 11/2020 - 01/2017
2	Anemia 07/2020 - 01/2014
2	Hypertension (High Blood Pressure) 07/2019 - 01/2017
2	Splenomegaly 01/2019 - 02/2014

Drug/Important Bio-Agent (IBA)

52	AutoantibodiesIBA 11/2022 - 02/2002
39	AntibodiesIBA 01/2022 - 12/2003
18	Proteins (Proteins, Gene)FDA Link 11/2022 - 12/2002
14	Biological ProductsIBA 05/2020 - 04/2007
12	Biomarkers (Surrogate Marker)IBA 10/2020 - 02/2012
12	Immunoglobulin G (IgG)IBA 05/2020 - 10/2010
12	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 01/2019 - 09/2004
11	GlucocorticoidsIBA 05/2020 - 01/2012
10	Methotrexate (Mexate)FDA LinkGeneric 05/2020 - 01/2005
10	Antirheumatic Agents (DMARD)IBA 10/2019 - 03/2009
9	HLA-DRB1 Chains (HLA DRB1)IBA 10/2020 - 09/2004
9	AutoantigensIBA 01/2018 - 12/2002
9	EnzymesIBA 12/2016 - 09/2002
8	AntigensIBA 01/2018 - 12/2002
8	Peptides (Polypeptides)IBA 01/2018 - 05/2005
7	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2009
7	Anti-Citrullinated Protein AntibodiesIBA 10/2020 - 11/2005
7	beta-cyclodextrin tetradecasulfate (CTDS)IBA 01/2019 - 05/2005
6	Abatacept (Orencia)FDA Link 02/2022 - 07/2016
6	Ligases (Synthetase)IBA 01/2022 - 12/2003
6	CytokinesIBA 11/2020 - 01/2002
6	Rheumatoid FactorIBA 10/2020 - 12/2014
5	Ferritins (Ferritin)IBA 11/2020 - 01/2007
5	RNA (Ribonucleic Acid)IBA 05/2020 - 12/2003
5	Tacrolimus (Prograf)FDA LinkGeneric 01/2020 - 06/2012
5	EpitopesIBA 11/2019 - 10/2010
5	Rituximab (Mabthera)FDA Link 01/2017 - 04/2007
5	Amino Acids FDA Link 08/2016 - 10/2013
5	Antinuclear AntibodiesIBA 01/2016 - 09/2004
5	Interleukin-6 (Interleukin 6)IBA 07/2014 - 02/2004
5	Interleukin-17 (Interleukin 17)IBA 07/2014 - 08/2009
5	Transfer RNA (tRNA)IBA 01/2014 - 12/2003
4	Infliximab (Remicade)FDA Link 01/2020 - 01/2011
4	iguratimodIBA 03/2019 - 05/2013
4	tocilizumab (atlizumab)FDA Link 03/2017 - 01/2009
4	Prednisolone (Predate)FDA LinkGeneric 01/2017 - 01/2007
4	ImmunosorbentsIBA 12/2016 - 12/2003
4	Pharmaceutical PreparationsIBA 01/2016 - 01/2007
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2008 - 12/2003
3	Peroxidase (Myeloperoxidase)IBA 12/2021 - 10/2017
3	SteroidsIBA 05/2020 - 01/2007
3	Adalimumab (Humira)FDA Link 05/2020 - 06/2016
3	InterleukinsIBA 09/2019 - 01/2007
3	HLA-B Antigens (HLA-B)IBA 12/2018 - 08/2013
3	Complement System Proteins (Complement)IBA 09/2018 - 06/2010
3	Etanercept (Enbrel)FDA Link 03/2013 - 05/2010
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2013 - 09/2004
3	Monoclonal AntibodiesIBA 04/2007 - 02/2004
3	FollistatinIBA 02/2004 - 12/2002
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2022 - 01/2012
2	Signal Recognition ParticleIBA 01/2022 - 12/2016
2	cyclic citrullinated peptideIBA 10/2020 - 02/2020
2	Class E Scavenger Receptors (Lectin Like Oxidized Low Density Lipoprotein Receptor 1)IBA 10/2020 - 09/2016
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 06/2012
2	Interleukin-2 Receptors (IL 2 Receptor)IBA 09/2019 - 09/2018
2	glucose utilization inhibitor (IGU)IBA 03/2019 - 09/2017
2	Calcineurin InhibitorsIBA 01/2019 - 06/2012
2	anti-dsDNA autoantibodyIBA 01/2019 - 01/2011
2	Interleukin-2 (IL2)IBA 09/2018 - 07/2018
2	C-Reactive ProteinIBA 09/2018 - 01/2007
2	Isoleucine-tRNA LigaseIBA 05/2017 - 01/2012

Therapy/Procedure

24	Therapeutics 01/2022 - 10/2003
2	Plasma Exchange 11/2020 - 01/2017
2	Remission Induction 09/2019 - 12/2017